Literature DB >> 24525454

Post-transcriptional regulation of human breast cancer cell proteome by unliganded estrogen receptor β via microRNAs.

Giovanni Nassa1, Roberta Tarallo, Giorgio Giurato, Maria Rosaria De Filippo, Maria Ravo, Francesca Rizzo, Claudia Stellato, Concetta Ambrosino, Marc Baumann, Niina Lietzèn, Tuula A Nyman, Alessandro Weisz.   

Abstract

Estrogen receptor β (ERβ) is a member of the nuclear receptor family of homeostatic regulators that is frequently lost in breast cancer (BC), where its presence correlates with a better prognosis and a less aggressive clinical outcome of the disease. In contrast to ERα, its closest homolog, ERβ shows significant estrogen-independent activities, including the ability to inhibit cell cycle progression and regulate gene transcription in the absence of the ligand. Investigating the nature and extent of this constitutive activity of ERβ in BC MCF-7 and ZR-75.1 cells by means of microRNA (miRNA) sequencing, we identified 30 miRNAs differentially expressed in ERβ+ versus ERβ- cells in the absence of ligand, including up-regulated oncosuppressor miRs such miR-30a. In addition, a significant fraction of >1,600 unique proteins identified in MCF-7 cells by iTRAQ quantitative proteomics were either increased or decreased by ERβ, revealing regulation of multiple cell pathways by ligand-free receptors. Transcriptome analysis showed that for a large number of proteins regulated by ERβ, the corresponding mRNAs are unaffected, including a large number of putative targets of ERβ-regulated miRNAs, indicating a central role of miRNAs in mediating BC cell proteome regulation by ERβ. Expression of a mimic of miR-30a-5p, a direct target and downstream effector of ERβ in BC, led to the identification of several target transcripts of this miRNA, including 11 encoding proteins whose intracellular concentration was significantly affected by unliganded receptor. These results demonstrate a significant effect of ligand-free ERβ on BC cell functions via modulation of the cell proteome and suggest that miRNA regulation might represent a key event in the control of the biological and clinical phenotype of hormone-responsive BC by this nuclear receptor.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24525454      PMCID: PMC3977185          DOI: 10.1074/mcp.M113.030403

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  78 in total

1.  Viral delivery of miR-196a ameliorates the SBMA phenotype via the silencing of CELF2.

Authors:  Yu Miyazaki; Hiroaki Adachi; Masahisa Katsuno; Makoto Minamiyama; Yue-Mei Jiang; Zhe Huang; Hideki Doi; Shinjiro Matsumoto; Naohide Kondo; Madoka Iida; Genki Tohnai; Fumiaki Tanaka; Shin-ichi Muramatsu; Gen Sobue
Journal:  Nat Med       Date:  2012-07       Impact factor: 53.440

2.  MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer.

Authors:  Regalla Kumarswamy; Giridhar Mudduluru; Paolo Ceppi; Santoshi Muppala; Miroslaw Kozlowski; Jacek Niklinski; Mauro Papotti; Heike Allgayer
Journal:  Int J Cancer       Date:  2011-08-08       Impact factor: 7.396

3.  Effects of oestrogen on microRNA expression in hormone-responsive breast cancer cells.

Authors:  Lorenzo Ferraro; Maria Ravo; Giovanni Nassa; Roberta Tarallo; Maria Rosaria De Filippo; Giorgio Giurato; Francesca Cirillo; Claudia Stellato; Silvana Silvestro; Concita Cantarella; Francesca Rizzo; Daniela Cimino; Olivier Friard; Nicoletta Biglia; Michele De Bortoli; Luigi Cicatiello; Ernesto Nola; Alessandro Weisz
Journal:  Horm Cancer       Date:  2012-06       Impact factor: 3.869

4.  MiR-30a-5p suppresses tumor growth in colon carcinoma by targeting DTL.

Authors:  Alexander Baraniskin; Karin Birkenkamp-Demtroder; Abdelouahid Maghnouj; Hannah Zöllner; Johanna Munding; Susanne Klein-Scory; Anke Reinacher-Schick; Irmgard Schwarte-Waldhoff; Wolff Schmiegel; Stephan A Hahn
Journal:  Carcinogenesis       Date:  2012-01-27       Impact factor: 4.944

5.  TRPS1 targeting by miR-221/222 promotes the epithelial-to-mesenchymal transition in breast cancer.

Authors:  Susanna Stinson; Mark R Lackner; Alex T Adai; Nancy Yu; Hyo-Jin Kim; Carol O'Brien; Jill Spoerke; Suchit Jhunjhunwala; Zachary Boyd; Thomas Januario; Robert J Newman; Peng Yue; Richard Bourgon; Zora Modrusan; Howard M Stern; Søren Warming; Frederic J de Sauvage; Lukas Amler; Ru-Fang Yeh; David Dornan
Journal:  Sci Signal       Date:  2011-06-14       Impact factor: 8.192

6.  MicroRNA-30a inhibits cell migration and invasion by downregulating vimentin expression and is a potential prognostic marker in breast cancer.

Authors:  Chun-Wen Cheng; Hsiao-Wei Wang; Chia-Wei Chang; Hou-Wei Chu; Cheng-You Chen; Jyh-Cherng Yu; Jui-I Chao; Huei-Fang Liu; Shian-Ling Ding; Chen-Yang Shen
Journal:  Breast Cancer Res Treat       Date:  2012-04-04       Impact factor: 4.872

7.  Direct regulation of microRNA biogenesis and expression by estrogen receptor beta in hormone-responsive breast cancer.

Authors:  O Paris; L Ferraro; O M V Grober; M Ravo; M R De Filippo; G Giurato; G Nassa; R Tarallo; C Cantarella; F Rizzo; A Di Benedetto; M Mottolese; V Benes; C Ambrosino; E Nola; A Weisz
Journal:  Oncogene       Date:  2012-01-09       Impact factor: 9.867

Review 8.  Aromatase, aromatase inhibitors, and breast cancer.

Authors:  Saranya Chumsri; Timothy Howes; Ting Bao; Gauri Sabnis; Angela Brodie
Journal:  J Steroid Biochem Mol Biol       Date:  2011-02-16       Impact factor: 4.292

9.  Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs.

Authors:  David M Garcia; Daehyun Baek; Chanseok Shin; George W Bell; Andrew Grimson; David P Bartel
Journal:  Nat Struct Mol Biol       Date:  2011-09-11       Impact factor: 15.369

10.  MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status.

Authors:  Xin Zhou; Catalin Marian; Kepher H Makambi; Ourania Kosti; Bhaskar V S Kallakury; Christopher A Loffredo; Yun-Ling Zheng
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

View more
  16 in total

1.  Leveraging the complementary nature of RNA-Seq and shotgun proteomics data.

Authors:  Xiaojing Wang; Qi Liu; Bing Zhang
Journal:  Proteomics       Date:  2014-11-17       Impact factor: 3.984

Review 2.  miRNAs regulated by estrogens, tamoxifen, and endocrine disruptors and their downstream gene targets.

Authors:  Carolyn M Klinge
Journal:  Mol Cell Endocrinol       Date:  2015-02-03       Impact factor: 4.102

3.  Small non-coding RNA deregulation in endometrial carcinogenesis.

Authors:  Maria Ravo; Angela Cordella; Antonio Rinaldi; Giuseppina Bruno; Elena Alexandrova; Pasquale Saggese; Giovanni Nassa; Giorgio Giurato; Roberta Tarallo; Giovanna Marchese; Francesca Rizzo; Claudia Stellato; Rossella Biancardi; Jacopo Troisi; Attilio Di Spiezio Sardo; Fulvio Zullo; Alessandro Weisz; Maurizio Guida
Journal:  Oncotarget       Date:  2015-03-10

4.  Integrative Omics Analysis Reveals Post-Transcriptionally Enhanced Protective Host Response in Colorectal Cancers with Microsatellite Instability.

Authors:  Qi Liu; Bing Zhang
Journal:  J Proteome Res       Date:  2015-12-29       Impact factor: 4.466

5.  Large-scale profiling of signalling pathways reveals an asthma specific signature in bronchial smooth muscle cells.

Authors:  Elena Alexandrova; Giovanni Nassa; Giacomo Corleone; Anton Buzdin; Alexander M Aliper; Nadezhda Terekhanova; Denis Shepelin; Alexander Zhavoronkov; Michael Tamm; Luciano Milanesi; Nicola Miglino; Alessandro Weisz; Pieter Borger
Journal:  Oncotarget       Date:  2016-05-03

6.  MicroRNA-30a increases tight junction protein expression to suppress the epithelial-mesenchymal transition and metastasis by targeting Slug in breast cancer.

Authors:  Chia-Wei Chang; Jyh-Cherng Yu; Yi-Hsien Hsieh; Chung-Chin Yao; Jui-I Chao; Po-Ming Chen; Hsiao-Yen Hsieh; Chia-Ni Hsiung; Hou-Wei Chu; Chen-Yang Shen; Chun-Wen Cheng
Journal:  Oncotarget       Date:  2016-03-29

7.  Estrogen receptor beta impacts hormone-induced alternative mRNA splicing in breast cancer cells.

Authors:  Dougba Noel Dago; Claudio Scafoglio; Antonio Rinaldi; Domenico Memoli; Giorgio Giurato; Giovanni Nassa; Maria Ravo; Francesca Rizzo; Roberta Tarallo; Alessandro Weisz
Journal:  BMC Genomics       Date:  2015-05-09       Impact factor: 3.969

8.  RNA sequencing identifies specific PIWI-interacting small non-coding RNA expression patterns in breast cancer.

Authors:  Adnan Hashim; Francesca Rizzo; Giovanna Marchese; Maria Ravo; Roberta Tarallo; Giovanni Nassa; Giorgio Giurato; Gianluca Santamaria; Angela Cordella; Concita Cantarella; Alessandro Weisz
Journal:  Oncotarget       Date:  2014-10-30

9.  Leptin as a mediator of tumor-stromal interactions promotes breast cancer stem cell activity.

Authors:  Cinzia Giordano; Francesca Chemi; Salvatore Panza; Ines Barone; Daniela Bonofiglio; Marilena Lanzino; Angela Cordella; Antonella Campana; Adnan Hashim; Pietro Rizza; Antonella Leggio; Balázs Győrffy; Bruno M Simões; Robert B Clarke; Alessandro Weisz; Stefania Catalano; Sebastiano Andò
Journal:  Oncotarget       Date:  2016-01-12

10.  The nuclear receptor ERβ engages AGO2 in regulation of gene transcription, RNA splicing and RISC loading.

Authors:  Roberta Tarallo; Giorgio Giurato; Giuseppina Bruno; Maria Ravo; Francesca Rizzo; Annamaria Salvati; Luca Ricciardi; Giovanna Marchese; Angela Cordella; Teresa Rocco; Valerio Gigantino; Biancamaria Pierri; Giovanni Cimmino; Luciano Milanesi; Concetta Ambrosino; Tuula A Nyman; Giovanni Nassa; Alessandro Weisz
Journal:  Genome Biol       Date:  2017-10-06       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.